VRSRF yields 20000000.00% · JNJ yields 2.13%● Live data
📍 VRSRF pulled ahead of the other in Year 1
Combined, VRSRF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of VRSRF + JNJ for your $10,000?
Versarien plc, an engineering materials company, provides engineering solutions for various industry sectors in the United Kingdom, rest of Europe, North America, and internationally. The company operates in two segments, Graphene and Plastic Products, and Hard Wear and Metallic Products. The Graphene and Plastic Products segment offers graphene products, such as Nanene, a few-layer graphene; Polygrene, a graphene enhanced polymer; Hexotene, a few-layer hexagonal boron nitride nano-platelet powder; and graphene-based nanomaterials for energy storage devices, as well as a range of electrically conductive graphene inks for various printing processes, substrates, and applications under the Graphinks name. This segment also provides graphene enhanced plastic products, including graphene enhanced mobile accessories, injection molding products, tool boxes, transit trays, PU foam tanks, and vacuum forming products. The Hard Wear and Metallic Products segment also offers sintered tungsten carbide products comprising special inserts and blanks, cutting knives, wear-resistant parts, nozzles and valve inserts for flow control, and defense and aerospace tungsten carbide parts for use in arduous environmental applications; and micro-porous metals for the thermal management industry, as well as supplies extruded aluminum products, such as aluminum industrial products and aluminum heat sinks. It also manufactures, sells, and supplies anti-bacterial and antiviral masks; and hospital bed panels and visors. The company was founded in 2010 and is based in Cheltenham, the United Kingdom.
Full VRSRF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.